Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Operating Leases (2020 - 2025)

Precision Biosciences (DTIL) has disclosed Operating Leases for 6 consecutive years, with $4.9 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 23.53% to $4.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, down 23.53% year-over-year, with the annual reading at $4.9 million for FY2025, 23.53% down from the prior year.
  • Operating Leases for Q4 2025 was $4.9 million at Precision Biosciences, down from $6.8 million in the prior quarter.
  • The five-year high for Operating Leases was $8.1 million in Q1 2021, with the low at $1.1 million in Q4 2022.
  • Average Operating Leases over 5 years is $5.6 million, with a median of $6.4 million recorded in 2024.
  • The sharpest move saw Operating Leases tumbled 78.0% in 2022, then soared 629.27% in 2023.
  • Over 5 years, Operating Leases stood at $4.8 million in 2021, then tumbled by 78.0% to $1.1 million in 2022, then skyrocketed by 629.27% to $7.7 million in 2023, then decreased by 17.08% to $6.4 million in 2024, then decreased by 23.53% to $4.9 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $4.9 million, $6.8 million, and $7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.